

15 Koronare Interventionen

15.1 Einleitung

- [1] Grüntzig A. Transluminal dilatation of coronary-artery stenosis. *Lancet* 1:263, 1978
- [2] Deutsche Herzstiftung e.V. 30./32./34. Herzbericht der Deutschen Herzstiftung, Frankfurt 2018/2020/2022
- [3] Görges G, Haude M, Ge J et al. Intravascular ultrasound after low and high inflation pressure coronary artery stent implantation. *J Am Coll Cardiol* 26:725–30, 1995
- [4] Colombo A, Hall P, Nakamura S et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. *Circulation* 91:1676–88, 1995
- [5] Morice MC, Zémour G, Benveniste E et al. Intracoronary stenting without coumadin: one month results of a French multicenter study. *Cathet Cardiovasc Diagn* 35:1–7, 1995
- [6] Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med* 346:1773–80, 2002
- [7] Bønaa KH, Mannsverk J, Wiseth R et al. Drug-eluting or bare-metal stents for coronary artery disease. *N Engl J Med* 375:1242–52, 2016
- [8] Ellis SG, Kereiakes DJ, Metzger DC et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. *N Engl J Med* 373:1905–15, 2015
- [9] Jeżewski MP, Kubisa MJ, Eyileten C et al. Bioresorbable vascular scaffolds – dead end or still a rough diamond? *J Clin Med* 8:2167, 2019
- [10] Serruys PW, Chevalier B, Sotomi Y et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. *Lancet* 388:2479–91, 2016
- [11] Wykrzykowska JJ, Kraak RP, Hofma SH et al. Bioresorbable scaffolds versus metallic stents in routine PCI. *N Engl J Med* 376:2319–28, 2017
- [12] Chevalier B, Cequier A, Dudek D et al. Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial) *EuroIntervention* 13:1561–4, 2018
- [13] Boeder NF, Weissner M, Blachutzik F et al. Incidental finding of strut malapposition is a predictor of late and very late thrombosis in coronary bioresorbable scaffolds. *J Clin Med* 8:580, 2019
- [14] Dimitriadis Z, Polimeni A, Anadol R et al. Procedural predictors for bioresorbable vascular scaffold thrombosis: analysis of the individual components of the „PSP“ technique. *J Clin Med* 8:93, 2019
- [15] Gori T, Polimeni A, Indolfi C et al. Predictors of stent thrombosis and their implications for clinical practice. *Nat Rev Cardiol* 16:243–56, 2019
- [16] Heublein B, Rohde R, Hausdorf G et al. Bio-corrosion – a new principle for temporary cardiovascular implants. *Eur Heart J* 21:286, 2000
- [17] Erbel R, Di Mario C, Bartunek J et al., PROGRESS-AMS (Clinical Performance and Angiographic Results of Coronary Stenting with Absorbable Metal Stents) Investigators. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. *Lancet* 369:1869–75, 2007
- [18] Böse D, Eggebrecht H, Erbel R. Absorbable metal stent in human coronary arteries: imaging with intravascular ultrasound. *Heart* 92:892, 2006
- [19] Lind AY, Eggebrecht H, Erbel R. The invisible stent: imaging of an absorbable me-

- tal stent with multislice spiral computed tomography. *Heart* 91:1604, 2005
- [20] Erbel R, Böse D, Haude M et al. Absorbierbare Stents: Eine vielversprechende Neuerung? *Herz* 32:308–19, 2007
- [21] Eggebrecht H, Rodermann J, Hunold P et al. Images in cardiovascular medicine. Novel magnetic resonance-compatible coronary stent: the absorbable magnesium-alloy stent. *Circulation* 112:e303–4, 2005
- [22] Haude M, Erbel R, Erne P et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. *Lancet* 381:836–44, 2013
- [23] Haude M, Ince H, Abizaid A et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. *Lancet* 387:31–9, 2016
- [24] Haude M, Ince H, Toelg R et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: three-year clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. *EuroIntervention* 15:e1375–82, 2020
- [25] Timmis A, Townsend N, Gale C et al., ESC Scientific Document Group. European Society of Cardiology: Cardiovascular Disease Statistics 2017. *Eur Heart J* 39:508–79, 2018
- [25a] Timmis A, Townsend N, Gale CP et al., European Society of Cardiology. European Society of Cardiology: Cardiovascular Disease Statistics 2019. *Eur Heart J* 41:12–85, 2020. Erratum in: *Eur Heart J* 41:4507, 2020
- [26] Meier B. The coronary stent saga. *Cardio-Update* 2E-800-1647-1:20–7, 2007
- [26a] Praz L, Cook S, Meier B, Working Group of Interventional Cardiology (WG 10) of the European Society of Cardiology/European Association of Percutaneous Cardiovascular Interventions (EAPCI). Percutaneous coronary interventions in Europe in 2005. *EuroIntervention* 3:442–6, 2008
- [27] Cook S, Togni M, Walpoth N et al. Percutaneous coronary interventions in Europe 1992–2003. *EuroIntervention* 1:374–9, 2006
- [28] Praz L, Cook S, Meier B. Percutaneous coronary interventions in Europe in 2005. *EuroIntervention* 3:442–6, 2008
- [29] Gajanana D, Weintraub WS, Kolm P et al. Trends in death rate 2009 to 2018 following percutaneous coronary intervention stratified by acuteness of presentation. *Am J Cardiol* 124:1349–56, 2019
- [30] Hulme WJ, Sperrin M, Martin GP et al., British Cardiovascular Intervention Society and the National Institute of Cardiovascular Outcomes Research. Temporal trends in relative survival following percutaneous coronary intervention. *BMJ Open* 9:e024627, 2019
- [31] Thygesen K, Alpert JS, Jaffe AS et al. Fourth universal definition of myocardial infarction (2018). *Eur Heart J* 40:237–69, 2019
- [32] Eggebrecht H, Ritzel A, von Birgelen C et al. Acute and long-term outcome after coronary artery perforation during percutaneous coronary interventions. *Z Kardiol* 93:791–8, 2004
- [33] Parsh J, Seth M, Green J et al. Coronary artery perforations after contemporary percutaneous coronary interventions: evaluation of incidence, risk factors, outcomes, and predictors of mortality. *Catheter Cardiovasc Interv* 89:966, 2017
- [34] Elison D, Dean LS. Cover up: Clinic outcomes of covered stent usage for coronary perforation during PCI. *Catheter Cardiovasc Interv* 96:1367–8, 2020
- [35] Verevkin A, von Aspern K, Leontyev S et al. Early and long-term outcomes in patients undergoing cardiac surgery following iatrogenic injuries during percutaneous coronary intervention. *J Am Heart Assoc* 8:e010940, 2019
- [36] Slottosch I, Liakopoulos O, Kuhn E et al. Outcome after coronary bypass grafting for coronary complications following coronary angiography. *J Surg Res* 210:69, 2017
- [37] Windecker S, Stortecky S, Stefanini GG et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. *BMJ* 348:g3859, 2014
- [38] Maron DJ, Hochman JS, Reynolds HR et al., ISCHEMIA Research Group. Initial invasive or conservative strategy for stable

- coronary disease. *N Engl J Med* 382:1395–407, 2020
- [39] Koslowski B. The Essen myocardial infarction network as a model of integrated medical care in the realization of the therapy of acute ST segment elevation myocardial infarction corresponding to guidelines. *Herz* 30:715–20, 2005
- [40] Scholz KH, Maier SK, Jung J et al. Reduction in treatment times through formalized data feedback: results from a prospective multicenter study of ST-segment elevation myocardial infarction. *JACC Cardiovasc Interv* 5:848–57, 2012
- [41] Scholz KH, Friede T, Meyer T et al. Prognostic significance of emergency department bypass in stable and unstable patients with ST-segment elevation myocardial infarction. *Eur Heart J Acute Cardiovasc Care* 9 (Suppl 1):34–44, 2020
- [42] Löwel H, Meisinger C, Heier M et al. Herzinfarkt und koronare Sterblichkeit in Süddeutschland. *Dtsch Ärzteblatt* 103:527–33, 2006
- nary atherosclerosis: the Heinz Nixdorf Recall study. *J Am Coll Cardiol* 56:1397–406, 2010
- [6] Erbel R. The dawn of a new era – non-invasive coronary imaging. *Herz* 21:75–7 1996
- [7] Greenland P, Blaha MJ, Budoff MJ et al. Coronary calcium score and cardiovascular risk. *J Am Coll Cardiol* 72:434–47, 2018
- [8] Figulla HR, Lauten A, Maier LS et al. Percutaneous coronary intervention in stable coronary heart disease – is less more? *Dtsch Arztebl Int* 117:137–44, 2020
- [9] Erbel R, Budoff M. Improvement of cardiovascular risk prediction using coronary imaging: subclinical atherosclerosis: the memory of lifetime risk factor exposure. *Eur Heart J* 33:1201–13, 2012
- [10] Maron DJ, Hochman JS, Reynolds HR et al., ISCHEMIA Research Group. Initial invasive or conservative strategy for stable coronary disease. *N Engl J Med* 382:1395–407, 2020
- [11] Knuuti J, Wijns W, Saraste A et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J* 41:407–77, 2020
- [11a] Nef HM, Achenbach S, Birkemeyer R et al. Manual der Arbeitsgruppe interventionelle Kardiologie (AGIK) der Deutschen Gesellschaft für Kardiologie – Herz-Kreislaufforschung e.V. (DGK) Teil 2: Durchführung der perkutanen Koronarintervention. *Kardiologie* 15:542–584, 2021
- [12] Neumann FJ, Sousa-Uva M, Ahlsson A et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 40:87–165, 2019
- [13] Alfonso F, Pérez-Vizcayno MJ, Cárdenas A et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). *J Am Coll Cardiol* 63:1378–86, 2014
- [14] Alfonso F, Pérez-Vizcayno MJ, Cárdenas A et al. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV randomized clinical trial. *J Am Coll Cardiol* 66:23–33, 2015

15.2 Koronare interventionelle Revaskularisierung

- [1] Bonzel T, Erbel R, Hamm CW et al. Perkutane Koronarinterventionen (PCI). *Clin Res Cardiol* 97:513–47, 2008
- [2] Maseri A, L'Abbate A, Chierchia S et al. Significance of spasm in the pathogenesis of ischemic heart disease. *Am J Cardiol* 44:788–92, 1979
- [3] Sigwart U, Grbic M, Payot M et al. Ischemic events during coronary artery balloon obstruction. In: Rutishauser W, Roskamm H (Eds), *Silent myocardial ischemia*. 29–36. Springer, Berlin, 1984
- [3a] Conti CR, Bavry AA, Petersen JW. Silent ischemia: clinical relevance. *J Am Coll Cardiol* 59:435–41, 2012
- [4] Erbel R, Hüttemann M, Schreiner G et al. Ischemia tolerance of the heart in percutaneous transluminal coronary angioplasty. Controlled study of the effect of isosorbide dinitrate and nifedipine. *Herz* 12:302–11, 1987
- [5] Erbel R, Möhlenkamp S, Moebus S et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coro-

- [15] Siontis GC, Stefanini GG, Mavridis D et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. *Lancet* 386:655–64, 2015
- [17] Giacoppo D, Gargiulo G, Aruta P et al. Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. *BMJ* 351:h5392, 2015
- [18] Hachamovitch R, Rozanski A, Shaw LJ et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. *Eur Heart J* 32:1012–24, 2011
- [19] Parasca CA, Head SJ, Milojevic M et al. Incidence, characteristics, predictors, and outcomes of repeat revascularization after percutaneous coronary intervention and coronary artery bypass grafting: the SYN-TAX Trial at 5 years. *JACC Cardiovasc Interv* 9:2493–507, 2016
- [20] Flaker G, Lopes RD, Hylek E et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. *J Am Coll Cardiol* 64:1541–50, 2014
- [21] Barbato E, Toth GG, Johnson NP et al. A prospective natural history study of coronary atherosclerosis using fractional flow reserve. *J Am Coll Cardiol* 68:2247–55, 2016
- [22] Trikalinos TA, Alsheikh-Ali AA, Tatsioni A et al. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. *Lancet* 373:911–8, 2009
- [23] Velazquez EJ, Lee KL, Deja MA et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. *N Engl J Med* 364:1607–16, 2011
- [24] Pursnani S, Korley F, Gopaul R et al. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. *Circ Cardiovasc Interv* 5:476–90, 2012
- [24a] Collet JP, Thiele H, Barbato E et al., ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 42:1289–367, 2021. Erratum in: *Eur Heart J* 42:1908, 2021. Erratum in: *Eur Heart J* 42:1925, 2021. Erratum in: *Eur Heart J* 42:2298, 2021.
- [24b] Granger CB, Goldberg RJ, Dabbous O et al., Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the global registry of acute coronary events. *Arch Intern Med* 163:2345–53, 2003
- [25] Eagle KA, Lim MJ, Dabbous OH et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. *JAMA* 291:2727–33, 2004
- [26] Mehta SR, Granger CB, Boden WE et al. Early versus delayed invasive intervention in acute coronary syndromes. *N Engl J Med* 360:2165–75, 2009
- [27] Koslowski B. The Essen myocardial infarction network as a model of integrated medical care in the realization of the therapy of acute ST segment elevation myocardial infarction corresponding to guidelines. *Herz* 30:715–20, 2005
- [28] Hailer B, Naber CK, Koslowski B et al., Herzinfarktverbund Essen. STEMI network Essen – results after 1 year. *Herz* 33:153–7, 2008
- [29] Jacksch R, Naber CK, Koslowski B et al., Herzinfarktverbund Essen. Primary Coronary Intervention (PCI) within the myocardial infarction network system in a German city (Essen). *Herz* 33:110–4, 2008
- [30] Erbel R. Treatment of acute myocardial infarction. *Herz* 33:85–6, 2008
- [31] Scholz KH, Maier SKG, Maier LS et al. Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial. *Eur Heart J* 39:1065–74, 2018
- [32] Ibáñez B, James S, Agewall S et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of

- the European Society of Cardiology (ESC). *Eur Heart J* 39:119–77, 2018
- [32a] Thrane PG, Olesen KKW, Thim T et al. Mortality Trends After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. *J Am Coll Cardiol* 82:999–1010, 2023
- [33] Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. *Lancet* 361:13–20, 2006
- [34] Boersma E. Primary coronary angioplasty vs. thrombolysis group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. *Eur Heart J* 27:779–88, 2006
- [35] Thiele H, Akin I, Sandri M et al. One-year outcomes after PCI strategies in cardiogenic shock. *N Engl J Med* 379:1699–710, 2018
- [36] Armstrong PW, Gershlick AH, Goldstein P et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. *N Engl J Med* 368:1379–87, 2013
- [37] Armstrong PW, Gershlick AH, Van de Werf F, STREAM Study Group. Fibrinolysis or primary PCI in myocardial infarction. *N Engl J Med* 369:280–1, 2013
- [38] Zeymer U, Bueno H, Granger CB et al. Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: a document of the Acute Cardiovascular Care Association of the European Society of Cardiology. *Eur Heart J Acute Cardiovasc Care* 9:183–97, 2020
- [39] Thiele H, Zeymer U, Neumann FJ et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. *N Engl J Med* 367:1287–96, 2012
- [40] Thiele H, Zeymer U, Thelemann N et al. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long-term 6-year outcome of the randomized IABP-SHOCK II trial. 139:395–403, 2019
- [41] Thiele H, Akin I, Sandri M et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. *N Engl J Med* 377:2419–32, 2017
- [41a] Thiele H, Zeymer U, Akin I et al. ECLS-SHOCK Investigators. Extracorporeal Life Support in Infarct-Related Cardiogenic Shock. *N Engl J Med*. 2023. Epub ahead of print. PMID:37634145, 2023
- [42] Erbel R. Myokardinfarkt. In: Burchardi H, Larsen R, Schuster H-P, Intensivmedizin. 9. Aufl., 515–48. Springer, Berlin, 2008
- [42a] Meyer J, Merx W, Dörr R et al. Successful treatment of acute myocardial infarction shock by combined percutaneous transluminal coronary recanalization (PTCR) and percutaneous transluminal coronary angioplasty (PTCA). *Am Heart J* 103:132–134, 1982
- [42b] Ostadal P, Rokyta R, Karasek J et al. ECMO-CS Investigators. Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial. *Circulation* 147:454–464, 2023
- [43] Pöss J, Köster J, Fuernau G et al. Risk stratification for patients in cardiogenic shock after acute myocardial infarction. *J Amer Coll Cardiol* 69:1913–20, 2017
- [44] Thiele H, Akin I, Sandri M et al. One-year outcomes after PCI strategies in cardiogenic shock. *N Engl J Med* 379:1699–710, 2018
- [45] Branco F. The heart and circulation – an integrative model. 2nd ed. Springer, New York, 2019
- [46] Erbel R, Heusch G. Koronare Mikroembolisierung – Rolle bei akutem Koronarsyndrom und Intervention. *Herz* 24:558–75, 1999
- [47] Erbel R, Heusch G. Coronary microembolization. *J Am Coll Cardiol* 36:22–4, 2000
- [48] Erbel R. Spontaneous and interventional coronary microembolization. *Heart* 89:986–9, 2003
- [49] Erbel R, Heusch G. Distale Embolisierung: Manifestation und Konsequenzen. *Herz* 29:716–21, 2004
- [50] Skyschally A, Schulz R, Haude M et al. Koronare Mikroembolisierung – Manifestation und klinische Konsequenzen. *Herz* 29:777–8, 2004
- [51] Heusch G, Kleinbongard P, Böse D et al. Coronary microembolization: from bedside to bench and back to bedside. *Circulation* 120:1822–36, 2009
- [52] Dörge H, Neumann T, Behrends M et al. Perfusion-contraction mismatch with coronary microvascular obstruction: role of

- inflammation. *Am J Physiol* 279: H2587–92, 2000
- [53] Skyschally A, Haude M, Dörge H et al. Glucocorticoid treatment prevents progressive myocardial dysfunction resulting from experimental coronary microembolization. *Circulation* 109:2337–42, 2004
- [54] Horn P, Baars T, Kahlert P et al. Release of intracoronary microparticles during stent implantation into stable atherosclerotic lesions under protection with an aspiration device. *PLoS One* 10:e0124904, 2015
- [55] Kleinbongard P, Baars T, Mohlenkamp S et al. Aspirate from human stented native coronary arteries vs. saphenous vein grafts: more endothelin but less particulate debris. *Am J Physiol Heart Circ Physiol* 305: H1222–9, 2013
- [56] Haude M, Altmann C, Eick B et al. Analysis of vessel wall morphology, blood flow velocity, and the hemostatic system in a patient with a large intracoronary thrombus. *Cathet Cardiovasc Diagn* 43:298–305, 1998
- [57] Baars T, Kleinbongard P, Boese D et al. Saphenous vein aorto-coronary graft atherosclerosis in patients with chronic kidney disease: more plaque calcification and necrosis, but less vasoconstrictor potential. *Basic Res Cardiol* 107:303, 2012
- [58] Kleinbongard P, Böse D, Baars T et al. Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. *Circ Res* 108:344–52, 2011
- [59] Angelini A, Rubartelli P, Mistrorigo F et al. Distal protection with a filter device during coronary stenting in patients with stable and unstable angina. *Circulation* 110:515–21, 2004
- [60] Mahmood A, Khair T, Abdel-Karim AR et al. Contemporary approaches to saphenous vein graft interventions: a survey of 275 interventional cardiologists. *Catheter Cardiovasc Interv* 79:834–42, 2012
- [61] Shoaib A, Kinnaird T, Curzen N et al. Outcomes following percutaneous coronary intervention in saphenous vein grafts with and without embolic protection devices. *JACC Cardiovasc Interv* 12:2286–95, 2019
- [62] Eick B, Haude M, Altmann C et al. Behandlung eines großen intrakoronaren Thrombus mit Urokinase und einem chimären monoklonalen Thrombozytenaggregationshemmer. *Dtsch Med Wochenschr* 122:709–15, 1997
- [63] Eggebrecht H, Baumgart D, Naber C et al. Extraction of large intracoronary thrombus in acute myocardial infarction by percutaneous Fogarty maneuver: intentional abuse of a novel interventional device. *Catheter Cardiovasc Interv* 55:228–32, 2002
- [64] Behan MW, Haude M, Oldroyd KG et al. Will this trial change my practice? TOTAL: a randomised trial of thrombus aspiration in ST-elevation myocardial infarction. *EuroIntervention* 11:361–3, 2015
- [65] Fröbert O, Lagerqvist B, Olivecrona GK et al. TASTE Trial. Thrombus aspiration during ST-segment elevation myocardial infarction. *N Engl J Med* 369:1587–97, 2013
- [66] Jolly SS, Cairns JA, Yusuf S et al., TOTAL Investigators. Randomized trial of primary PCI with or without routine manual thrombectomy. *N Engl J Med* 372:1389–98, 2015
- [67] Ito N, Nanto S, Doi Y et al. Distal protection during primary coronary intervention can preserve the index of microcirculatory resistance in patients with acute anterior ST-segment elevation myocardial infarction. *Circ J* 75:94–8, 2011
- [68] Gamou T, Sakata K, Matsubara T et al. Impact of thin-cap fibroatheroma on predicting deteriorated coronary flow during interventional procedures in acute as well as stable coronary syndromes: insights from optical coherence tomography analysis. *Heart Vessels* 30:719–27, 2015
- [70] Porto I, Belloni F, Niccoli G et al. Filter no-reflow during percutaneous coronary intervention of saphenous vein grafts: incidence, predictors and effect of the type of protection device. *EuroIntervention* 7:955–61, 2011
- [71] Kitagawa K, Amano T, Uetani T et al. Association between plaque characteristics and the amount of debris captured by a filter-type distal protection device in patients with acute coronary syndrome. *Atherosclerosis* 258:72–8, 2017
- [72] Teramoto R, Sakata K, Miwa K et al. Impact of distal protection with filter-type device on long-term outcome after percutaneous coronary intervention for acute myocardial infarction: clinical results with

- Filtrap. *J Atheroscler Thromb* 23:1313–23, 2016
- [73] Hibi K, Kozuma K, Sonoda S et al. A randomized study of distal filter protection versus conventional treatment during percutaneous coronary intervention in patients with attenuated plaque identified by intravascular ultrasound. *JACC Cardiovasc Interv* 11:1545–55, 2018
- [74] Kereiakes DJ, Turco MA, Breall J et al. A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions: results of the AMethyst randomized controlled trial. *JACC Cardiovasc Interv* 1:248–57, 2008
- [75] de Bruyne B, Bartunek J, Sys SU et al. Simultaneous coronary pressure and flow velocity measurements in humans. Feasibility, reproducibility, and hemodynamic dependence of coronary flow velocity reserve, hyperemic flow versus pressure slope index, and fractional flow reserve. *Circulation* 94:1842–9, 1996
- [76] Pijls NH, van Schaardenburgh P, Manoharan G et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. *J Am Coll Cardiol* 49:2105–11, 2007
- [77] Xaplanteris P, Fournier S, Pijls NHJ et al. Five-year outcomes with PCI guided by fractional flow reserve. *N Engl J Med* 379:250–9, 2018
- [78] DEFINE-FLAIR Trial Investigators, Lee JM, Choi KH, Koo BK et al. Comparison of major adverse cardiac events between instantaneous wave-free ratio and fractional flow reserve-guided strategy in patients with or without Type 2 diabetes: a secondary analysis of a randomized clinical trial. *JAMA Cardiol* 4:857–64, 2019
- [79] Driessen RS, de Waard GA, Stuijzand WJ et al. Adverse plaque characteristics relate more strongly with hyperemic fractional flow reserve and instantaneous wave-free ratio than with resting instantaneous wave-free ratio. *JACC Cardiovasc Imaging* 13:746–56, 2020
- [80] Arashi H, Satomi N, Ishida et al. Hemodynamic and lesion characteristics associated with discordance between the instantaneous wave-free ratio and fractional flow reserve. *J Interv Cardiol* 2019:3765282, 2019
- [81] Cook CM, Howard JP, Ahmad Y et al. How do fractional flow reserve, whole-cycle PdPa, and instantaneous wave-free ratio correlate with exercise coronary flow velocity during exercise-induced angina? *Circ Cardiovasc Interv* 13:e008460, 2020
- [82] Hwang D, Choi KH, Lee JM et al. Diagnostic agreement of quantitative flow ratio with fractional flow reserve and instantaneous wave-free ratio. *J Am Heart Assoc* 8:e011605, 2019
- [83] Abizaid AS, Mintz GS, Mehran R et al. Long-term follow-up after percutaneous transluminal coronary angioplasty was not performed based on intravascular ultrasound findings – importance of lumen dimensions. *Circulation* 100:256–61, 1999
- [84] Riccardi MJ, Meyers S, Choi K et al. Angiographically silent left main disease detected by intravascular ultrasound: a marker for future adverse cardiac events. *Am Heart J* 146:507–12, 2003
- [85] Okabe T, Mintz GS, Lee SY et al. Five-year outcomes of moderate or ambiguous left main coronary artery disease and the intravascular ultrasound predictors of events. *J Invasive Cardiol* 20:635–9, 2008
- [86] Gyongyosi M, Yang P, Hassan A et al. Intravascular ultrasound predictors of major adverse cardiac events in patients with unstable angina. *Clin Cardiol* 23:507–15, 2000
- [87] Gil RJ, Gziut AI, Prati F et al. Threshold parameters of left main coronary artery stem stenosis based on intracoronary ultrasound examination. *Kardiol Pol* 63:223–31, 2005
- [87a] Stone GW, Maehara A, Lansky AJ et al., PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. *N Engl J Med* 364:226–35, 2011
- [88] Erbel R, Ge J, Bockisch A et al. Value of intracoronary ultrasound and Doppler in the differentiation of angiographically normal coronary arteries: a prospective study in patients with angina pectoris. *Eur Heart J* 17:880–9, 1996
- [89] Baumgart D, Haude M, Goerge G et al. Improved assessment of coronary stenosis severity using the relative flow velocity reserve. *Circulation* 98:40–6, 1998
- [90] Baumgart D, Haude M, Liu F et al. Current concepts of coronary flow reserve for clinical decision making during cardiac ca-

theterization. *Am Heart J* 136:136–49, 1998

- [91] Haude M, Baumgart D, Verna E et al. Intracoronary Doppler- and quantitative coronary angiography-derived predictors of major adverse cardiac events after stent implantation. *Circulation* 103:1212–7, 2001
- [92] Peterson ED, Dai D, DeLong ER et al. Contemporary mortality risk prediction for percutaneous coronary intervention – results from 588,398 procedures in the National Cardiovascular Data Registry. *J Am Coll Cardiol* 55:1923–1932, 2010

15.3 Materialien für koronare Interventionen

15.3.1–15.3.3 Koronare Interventionen

- [1] Alfonso F, Pérez-Vizcayno MJ, Cárdenas A et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). *J Am Coll Cardiol* 63:1378–86, 2014
- [1a] Burke MN. Wire strategy as a first option: properties of the tools. *Interv Cardiol Clin* 1:309–14, 2012
- [2] Pleva L, Kukla P, Kusnierova P et al. Comparison of the efficacy of paclitaxel-eluting balloon catheters and everolimus-eluting stents in the treatment of coronary in-stent restenosis: the treatment of in-stent restenosis study. *Circ Cardiovasc Interv* 9:e003316, 2016
- [3] Habara S, Iwabuchi M, Inoue N et al. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. *Am Heart J* 166:527–33, 2013
- [4] Byrne RA, Neumann FJ, Mehilli J et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. *Lancet* 381:461–7, 2013
- [5] Alfonso F, Pérez-Vizcayno MJ, Cárdenas A et al. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV Randomized Clinical Trial. *J Am Coll Cardiol* 66:23–33, 2015
- [6] Baan J Jr, Claessen BE, Dijk KB et al. A randomized comparison of paclitaxel-eluting balloon versus everolimus-eluting stent for the treatment of any in-stent restenosis: the DARE Trial. *JACC Cardiovasc Interv* 11:275–83, 2018
- [7] Neumann FJ, Sousa-Uva M, Ahlsson A et al. ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 40:87–165, 2019 Erratum in: *Eur Heart J* 40:3096, 2019
- [8] Kufner S, Joner M, Schneider S et al. Neointimal modification with scoring balloon and efficacy of drug-coated balloon therapy in patients with restenosis in drug-eluting coronary stents: a randomized controlled trial. *JACC Cardiovasc Interv* 10:1222–9, 2017
- [9] Siontis GC, Stefanini GG, Mavridis D et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. *Lancet* 386:655–64, 2015
- [10] Giacoppo D, Gargiulo G, Aruta P et al. Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. *BMJ* 351:h5392, 2015
- [11] Kufner S, Cassese S, Valeskini M et al. Long-term efficacy and safety of paclitaxel-eluting balloon for the treatment of drug-eluting stent restenosis: 3-year results of a randomized controlled trial. *JACC Cardiovasc Interv* 8:877–84, 2015
- [12] Xu B, Qian J, Ge J et al. Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis. *Catheter Cardiovasc Interv* 87(Suppl 1):624–9, 2016
- [13] Byrne RA, Cassese S, Windisch T et al. Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: in-

sights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. *EuroIntervention* 9:797–802, 2013

15.3.4 Koronare Stents

- [1] O'Brien B, Carroll W. The evolution of cardiovascular stent materials and surfaces in response to clinical drivers: a review. *Acta Materialia* 5:945–58, 2009
- [1a] Schmidt T, Abbott JD. Coronary stents: history, design, and construction. *J Clin Med* 7:126, 2018
- [2] Kastrati A, Mehilli J, Dirschinger J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STERO) trial. *Circulation* 103:2816–21, 2001
- [3] Hoffmann R, Mintz GS, Haager PK et al. Relation of stent design and stent surface material to subsequent in-stent intimal hyperplasia in coronary arteries determined by intravascular ultrasound. *Am J Cardiol* 89:1360–4, 2002
- [4] Hausleiter J, Kastrati A, Mehilli J et al. Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STERO trial. *Am Heart J* 146:882–6, 2003
- [5] Rittersma SZ, de Winter RJ, Koch KT et al. Impact of strut thickness on late luminal loss after coronary artery stent placement. *Am J Cardiol* 93:477–80, 2004
- [6] Turco MA, Ormiston JA, Popma JJ et al. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program. *JACC Cardiovasc Interv* 1:699–709, 2008
- [7] Haidopoulos M. Development of an optimized electrochemical process for subsequent coating of L316 stainless steel for stent application. *J Mater Sci Mater Med* 17:647–57, 2006
- [8] Noad RL, Hanratty CG, Walsh SJ. Clinical impact of stent design. *Interv Cardiol* 9:89–93, 2014
- [9] Watson T, Webster MWI, Ormiston JA et al. Long and short of optimal stent design. *Open Heart* 4:e000680, 2017
- [10] Borhani S, Hassanajili S, Ahmadi Tafti SH et al. Cardiovascular stents: overview, evolution, and next generation. *Prog Biomater* 7:175–205, 2018
- [11] Torii S, Jinnouchi H, Sakamoto A et al. Drug-eluting coronary stents: insights from preclinical and pathology studies. *Nat Rev Cardiol* 17:37–51, 2020
- [11a] Christ G. Stents und Scaffolds. *J Kardiologie* 27:229–36, 2020
- [12] Strupp G, Schreiner G, Bonzel T. Bauarten und Eigenschaften koronarer Stents – „Stentmanual 2005“. 9. Aufl. Klinikum Fulda, Medizinische Klinik I, 2005
- [13] Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. *N Engl J Med* 331:489–95, 1994
- [14] Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. *N Engl J Med* 331:496–501, 1994
- [15] Erbel R, Haude M, Höpp HW et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. *N Engl J Med* 339:1672–8, 1998
- [16] Haude M, Hopp HW, Rupprecht HJ et al. Immediate stent implantation versus conventional techniques for the treatment of abrupt vessel closure or symptomatic dissections after coronary balloon angioplasty. *Am Heart J* 140:e26, 2000
- [17] Iqbal J, Gunn J, Serruys PW. Coronary stents: historical development, current status and future directions. *Br Med Bull* 106:193–211, 2013
- [18] Schmidt W, Lanzer P, Behrens P et al. Direct comparison of coronary bare metal vs. drug-eluting stents: same platform, different mechanics? *Eur J Med Res* 23:1–12, 2018. Original publisher: BMC – BioMed Central Ltd, Part of Springer Nature
- [18a] <https://www.xiencestent.com/us/complex-pci/xience-sierra-large-vessel-lesion> (abgerufen 17.1.2023)
- [18b] <https://www.xiencestent.com/us/complex-pci/xience-sierra-side-branch-stent> (abgerufen 17.1.2023)
- [18c] <https://www.bostonscientific.com/en-EU/products/stents-coronary/synergy->

- stent-system/megatron/visibility.html (abgerufen 17.1.2023)
- [18d] Schenk CD, Gebker R, Berger A et al. Review of safety reports of cardiac MR-imaging in patients with recently implanted coronary artery stents at various field strengths. *Expert Rev Med Devices* 18:83–90, 2021
- [19] Möhlenkamp S, Pump H, Ge J et al. Ein neuer Titan Stent: In-vitro-Charakteristika in der Elektronenstrahltomographie. *Z Kardiol* 86:3, 1997
- [20] Karjalainen PP, Ylitalo A, Airaksinen JK et al. Five-year clinical outcome of titanium-nitride-oxide-coated bioactive stent implantation in a real-world population: a comparison with paclitaxel-eluting stents: the PORI registry. *J Interv Cardiol* 24:1–8, 2011
- [21] Karjalainen PP, Ylitalo A, Airaksinen JK et al. Titanium-nitride-oxide-coated Titan-2 bioactive coronary stent: a new horizon for coronary intervention. *Expert Rev Med Devices* 7:599–604, 2010
- [22] Karjalainen PP, Nammas W. Titanium-nitride-oxide-coated coronary stents: insights from the available evidence. *Ann Med* 49:299–309, 2017
- [23] Antoniucci D, Bartorelli A, Valenti R et al. Clinical and angiographic outcome after coronary arterial stenting with the carbo-stent. *Am J Cardiol* 85:821–5, 2000
- [24] Wieneke H, Dirsch O, Sawitowski T et al. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. *Cath Cardiovasc Interv* 60:399–407, 2003
- [24a] Takami Y, Nakazawa T, Makinouchi K et al. Biocompatibility of alumina ceramic and polyethylene as materials for pivot bearings of a centrifugal blood pump. *J Biomed Mater Res* 36:381–6, 1997
- [24b] Eckert KL, Mathey M, Mayer J et al. Preparation and in vivo testing of porous alumina ceramics for cell carrier applications. *Biomaterials* 21:63–9, 2000
- [24c] Edelman ER, Seifert P, Morss GA et al. Gold-coated NIR stents in porcine coronary arteries. *Circulation* 103:429–34, 2001
- [25] Tur DS, Korshak SV, Vinogradova NB. Investigation of the thermostability of poly[bis(trifluoroethoxy)phosphazene]. *Acta Polymerica* 36:627–31, 1985
- [26] Welle A, Grunze M, Tur D. Plasma protein adsorption and platelet adhesion on poly[bis(trifluoroethoxy)phosphazene] and reference material surfaces. *J Colloid Interface Sci* 197:263–74, 1998
- [27] Unterberg C, Sandrock D, Nebendahl K et al. Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty. *J Am Coll Cardiol* 26:174–54, 1995
- [28] Prati F, Cera M, Ramazzotti V et al. Safety and feasibility of a new non-occlusive technique for facilitated intracoronary optical coherence tomography (OCT) acquisition in various clinical and anatomical scenarios. *EuroInterv* 3:365–70, 2007
- [29] Tamburino C, La Manna A, Di Salvo ME et al. First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The Latest Non-Thrombogenic Angioplasty stent) trial. *JACC Cardiol Interv* 2:197–204, 2009
- [30] Pourmoghaddas M, Rohani HR, Sanei H et al. Undesired outcomes of the catania stent compared to the Xience stent in patients undergoing angioplasty: a double-blind randomized controlled trial. *Adv Biomed Res* 6:154–8, 2017
- [31] Hasebe T, Yohena S, Kamijo A et al. Fluorine doping into diamond-like carbon coatings inhibits protein adsorption and platelet activation. *J Biomed Mater Res A* 83:1192–9, 2007
- [32] Rogers C, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. *Circulation* 91:2995–3001, 1995
- [33] Price MJ, Shlofmitz RA, Spriggs DJ et al. Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: primary outcome of the RESOLUTE ONYX core trial. *Catheter Cardiovasc Interv* 92:253–9, 2018
- [34] Jensen LO, Thayssen P, Christiansen EH et al. Safety and efficacy of everolimus-versus sirolimus-eluting stents: 5-year results from SORT OUT IV. *J Am Coll Cardiol* 67:751–62, 2016
- [35] Otsuka F, Vorpahl M, Nakano M et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. *Circulation* 129:211–23, 2014

- [36] Kandzari DE, Smits PC, Love MP et al. Randomized comparison of ridaforolimus- and zotarolimus-eluting coronary stents in patients with coronary artery disease: primary results from the BIONICS Trial (BioNIR ridaforolimus-eluting coronary stent system in coronary stenosis). *Circulation* 136:1304–14, 2017
- [37] El-Hayek G, Bangalore S, Casso Dominguez A et al. Meta-analysis of randomized clinical trials comparing biodegradable polymer drug-eluting stent to second-generation durable polymer drug-eluting stents. *JACC Cardiovasc Interv* 10:462–73, 2017
- [38] Torii S, Virmani R, Finn A. An uncommon but important cause of stent thrombosis: Kounis syndrome. *Cardiovasc Revasc Med* 19:818–9, 2018
- [39] Wiemer M, Butz T, Schmidt W et al. Scanning electron microscopic analysis of different drug eluting stents after failed implantation: from nearly undamaged to major damaged polymers catheter. *Cardiovasc Interv* 75:905–11, 2010
- [40] Basalus MW, Tandjung K, van Westen T et al. Scanning electron microscopic assessment of coating irregularities and their precursors in unexpanded durable polymer-based drug-eluting stents. *Catheter Cardiovasc Interv* 79:644–53, 2012
- [41] Basalus MW, Tandjung K, van Apeldoorn AA et al. Effect of oversized partial postdilatation on coatings of contemporary durable polymer-based drug-eluting stents: a scanning electron microscopy study. *J Interv Cardiol* 24:149–61, 2011
- [42] Ladich E, Vorpahl M, Nakano M et al. Late test on the pathology of drug-eluting stents. *Interv Cardiol* 1:165–74, 2009
- [43] Middleton JC, Tipton AJ. Synthetic biodegradable polymers as orthopedic devices. *Biomaterials* 21:2335–46, 2000
- [44] Grube E, Hauptmann KE, Buellesfeld L et al. Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coating. *EuroIntervention* 1:53–7, 2005
- [45] Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): a randomised non-inferiority trial. *Lancet* 372:1163–73, 2008
- [46] Hamilos MI, Ostojic M, Beleslin B et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. *J Am Coll Cardiol* 51:2123–9, 2008
- [49] Kandzari DE, Mauri L, Koolen JJ et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. *Lancet* 390:1843–52, 2017; Erratum in: *Lancet* 390:1832, 2017
- [50] Wani MC, Taylor HL, Wall ME et al. Plant antitumor agents. VI. The isolated and structure of taxol, a novel antileukemic and antitumor agent from *Taxus brevifolia*. *J Am Chem Soc* 93:2325–7, 1971
- [51] Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. *Nature* 277:665–7, 1979
- [52] Wieneke H, Schmermund A, van Birgelen C et al. Therapeutic potential of active stent coating. *Expert Opin Investig Drugs* 12:1–9, 2003
- [53] Wilson GJ, Nakazawa G, Schwartz RS et al. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. *Circulation* 120:141–9, 2009
- [54] Farb A, Heller PF, Shroff S et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. *Circulation* 104:473–9, 2001
- [55] Drachman DE, Edelman ER, Seifert P et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. *J Am Coll Cardiol* 36:2325–32, 2000
- [56] Ahmed W, Zambahari R, Al-Rashdan I et al. One-year outcome with the TAXUS Liberté stent in the real world: The TAXUS OLYMPIA Registry (Phase I). *J Interv Cardiol* 21:512–8, 2008
- [57] Turco MA, Ormiston JA, Popma JJ et al. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program. *JACC Cardiovasc Interv* 1:699–709, 2008
- [58] Mahmud E, Ormiston JA, Turco MA et al. TAXUS Liberté attenuates the risk of re-

- nosis in patients with medically treated diabetes mellitus: results from the TAXUS ATLAS program. *JACC Cardiovasc Interv* 2:240–52, 2009
- [59] Turco M, Ormiston J, Mandinov L et al. TAXUS ATLAS and TAXUS ATLAS DIRECT STENT trials: Durable effectiveness of the TAXUS Liberté stent and long-term benefit of direct stenting. *Am J Cardiol* 102(Suppl 1):147i, 2008
- [60] Moses JW, Stone GW, Nikolsky E et al. Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials. *J Am Coll Cardiol* 47:2164–71, 2006
- [61] Dawkins KD, Stone GW, Colombo A et al. Integrated analysis of medically treated diabetic patients in the TAXUS program: benefits across stent platforms, paclitaxel release formulations, and diabetic treatments. *EuroIntervention* 2:61–8, 2006
- [62] Ellis SG, Colombo A, Grube E et al. Incidence, timing, and correlates of stent thrombosis with the polymeric Paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. *J Am Coll Cardiol* 49:1043–51, 2007
- [63] Escolar E, Mintz GS, Popma J et al. Meta-analysis of angiographic versus intravascular ultrasound parameters of drug-eluting stent efficacy (from TAXUS IV, V, and VI). *Am J Cardiol* 100:621–6, 2007
- [64] Stone GW, Ellis SG, Colombo A et al. Off-setting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. *Circulation* 115:2842–7, 2007
- [65] Vezina C, Kudelski A, Seghal SN. Rapamycin (AY-22, 989), a new antifungal antibiotic, I: toxoneme of the producing streptomycete and isolation of the active principle. *J Antibiot (Tokyo)* 28:721–6, 1975
- [66] Gregory CR, Huie P, Billingham ME et al. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. *Transplantation* 55:1409–18, 1993
- [67] Sadoshima J, Izumo S. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. *Circ Res* 77:1040–52, 1995
- [68] Poon M, Marx SO, Gallo R et al. Rapamycin inhibits vascular smooth muscle cell migration. *J Clin Invest* 98:2277–83, 1996
- [69] Burke SE, Lubbers NL, Chen YW et al. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. *J Cardiovasc Pharmacol* 33:829–35, 1999
- [70] Sousa JE, Costa MA, Abizaid A et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. *Circulation* 103:192–5, 2001
- [71] Morice MC, Serruys PW, Sousa JE et al., RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med* 46(23):1773–80, 2002
- [72] Moses J, Leon MB, Popma JJ et al. SIRIUS: A US multicenter, randomised, double-blind study of the sirolimus-stent in de-novo native coronary lesions. 14th Annual Transcatheter Cardiovascular Therapeutics Meeting, Washington DC, USA, September 24–28, 2002
- [73] Sousa JE, Costa MA, Sousa AG et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. *Circulation* 107:381–3, 2003
- [74] Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? *Circulation* 109:701–5, 2004
- [75] Otsuka F, Yahagi K, Ladich E et al. Hypersensitivity reaction in the US Food and Drug Administration-approved second-generation drug-eluting stents: histopathological assessment with ex vivo optical coherence tomography. *Circulation* 131:322–4, 2015
- [76] Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. *N Engl J Med* 356:998–1008, 2007
- [77] Moses JW, Leon MB, Popma JJ et al. SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients

- with stenosis in a native coronary artery. *N Engl J Med* 349:1315–23, 2003
- [78] Togni M, Windecker S, Cocchia R et al. Sirolimus-eluting stents associated with paradoxical coronary vasoconstriction. *J Am Coll Cardiol* 46:231–6, 2005
- [79] Hofma SH, van der Giessen WJ, van Dalen BM et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. *Eur Heart J* 27:166–70, 2006
- [80] Marzocchi A, Saia F, Piovaccari G et al. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. *Circulation* 115:3181–8, 2007
- [81] Morice MC, Serruys PW, Barragan P et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. *J Am Coll Cardiol* 50:1299–304, 2007
- [82] Schampaert E, Moses JW, Schofer J et al. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. *Am J Cardiol* 98:36–41, 2006
- [83] Edelmann E, Falotico R, Parker T. Naevo sirolimus-eluting coronary stent. *Cardiac & Vascular update* 2:7–9, 2009
- [84] Wiemer M, Seth A, Chandra P et al. Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. *Am Heart J* 156:751.e1–7, 2008
- [85] Doros G, Massaro JM, Kandzari DE et al. Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach. *Am Heart J* 193:35–45, 2017
- [86] Saito S, Toelg R, Witzenbichler B et al. BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months. *EuroIntervention* 15:e1006–13, 2019
- [87] Kang SH, Chung WY, Lee JM et al. Angiographic outcomes of Orsiro biodegradable polymer sirolimus-eluting stents and Resolute Integrity durable polymer zotarolimus-eluting stents: results of the ORIENT trial. *EuroIntervention* 12:1623–31, 2017
- [88] van der Heijden LC, Kok MM, Zocca P et al. Bioresorbable polymer-coated orsiro versus durable polymer-coated Resolute Onyx stents (BIONYX): rationale and design of the randomized TWENTE IV multicenter trial. *Am Heart J* 198:25–32, 2018
- [89] von Birgelen C, Zocca P, Buiten RA et al. Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultra-thin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial. *Lancet* 392:1235–45, 2018
- [90] Godino C, Beneduce A, Ferrante G et al. One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in allcomers population. Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry). *Int J Cardiol* 260:36–41, 2018
- [91] de Winter RJ, Katagiri Y, Asano T et al. A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial. *Lancet* 391:431–40, 2018
- [92] Milewski K, Takahashi K, Asano T et al. Neointimal hyperplasia of ultra-thin stents with microcrystalline sirolimus or durable polymer everolimus-eluting stents: 6- and 24-month results of the DESSOLVE III OCT study. *EuroIntervention* 16:1187–94, 2021
- [93] Torguson R, Waksman R. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the Xience V everolimus-eluting coronary stent. *Am J Cardiol* 102:1624–30, 2008
- [94] Stone GW, Midei M, Newman W et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. *Circulation* 119:680–6, 2009

- [95] Onuma Y, Kukreja N, Piazza N et al. Interventional Cardiologists of the Thoraxcenter (2000 to 2007). The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry. *J Am Coll Cardiol* 54:269–76, 2009
- [96] Kedhi E, Joesoef KS, McFadden E et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. *Lancet* 375:201–9, 2000
- [97] Chang CC, Onuma Y, Achenbach S et al. Absorb bioresorbable scaffold versus Xience metallic stent for prevention of restenosis following percutaneous coronary intervention in patients at high risk of restenosis: rationale and design of the COMPARE ABSORB Trial. *Cardiovasc Res* 20:577–82, 2019
- [98] Nakamura M, Otsuji S, Nakagawa Y et al. Non-inferiority of Resolute Integrity drug-eluting stent to benchmark Xience drug-eluting stent. *Circ J* 82:2284–91, 2018
- [99] Vlachojannis GJ, Puricel S, Natsuaki M et al. Biolimus-eluting versus everolimus-eluting stents in coronary artery disease: a pooled analysis from the NEXT (NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent) and COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) randomised trials. *EuroIntervention* 12:1970–7, 2017
- [100] Windecker S, Stortecky S, Stefanini GG et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. *BMJ* 348:g3859, 2014
- [101] Mitsis A, Valgimigli M. Device profile of the XIENCE V and XIENCE Sierra stents for the treatment of coronary artery disease: an overview of safety and efficacy. *Expert Rev Med Devices* 17:383–90, 2020
- [102] Kogame N, Modolo R, Tomaniak M et al. Prasugrel monotherapy after PCI with the SYNERGY stent in patients with chronic stable angina or stabilised acute coronary syndromes: rationale and design of the ASET pilot study. *EuroIntervention* 15:e547–50, 2019
- [103] Shreenivas SS, Kereiakes DJ. Evolution of the SYNERGY bioresorbable polymer metallic coronary stent. *Future Cardiol* 14:307–17, 2018
- [104] Lopes RD, Heizer G, Aronson R et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. *N Engl J Med* 380:1509–24, 2019
- [105] Vranckx P, Valgimigli M, Jüni P et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. *Lancet* 392:940–9, 2018
- [106] Watanabe H, Domei T, Morimoto T et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial. *JAMA* 321:2414–27, 2019
- [107] Hahn JY, Song YB, Oh JH et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. *JAMA* 321:2428–37, 2019
- [108] Baber U, Dangas G, Cohen DJ et al. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: rationale and design of the TWILIGHT study. *Am Heart J* 182:125–34, 2016
- [108a] Escaned J, Cao D, Baber U et al. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. *Eur Heart J* 42:4624–34, 2021
- [109] Garcia-Touchard A, Burke SE, Toner JL et al. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. *Euro Heart J* 27:988–93, 2006
- [110] Lewis AL, Cumming ZL, Goreish HH et al. Cross-linkable coatings from phosphorylcholine-based polymers. *Biomaterials* 22:99–111, 2001
- [111] Lewis AL, Stratford PW. Phosphorylcholine-coated stents. *J Long Term Eff Med Implants* 12:231–50, 2002
- [112] Meredith IT, Ormiston J, Whitbourn R et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo na-

- tive coronary artery lesions: Endeavor I Trial. *EuroIntervention* 1:157–64, 2005
- [113] Meredith IT, Ormiston J, Whitbourn R et al., ENDEAVOR I Investigators. Five-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, first-in-human study. *Catheter Cardiovasc Interv* 74:989–95, 2009
- [114] Mehta RH, Leon MB, Sketch MH Jr. ENDEAVOR II Continued Access Registry. The relation between clinical features, angiographic findings, and the target lesion revascularization rate in patients receiving the endeavor zotarolimus-eluting stent for treatment of native coronary artery disease: an analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III. *Am J Cardiol* 100:62M–70M, 2007
- [115] Miyazawa A, Ako J, Hongo Y et al. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. *Am Heart J* 155:108–13, 2008
- [116] Leon MB, Nikolsky E, Cutlip DE et al. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease) trial. *JACC Cardiovasc Interv* 3:1043–50, 2010
- [117] Kirtane AJ, Leon MB, Ball MW et al. The „final“ 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. *JACC Cardiovasc Interv* 6:325–33, 2013
- [118] Vardi M, Burke DA, Bangalore S et al. Long-term efficacy and safety of zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials. *Catheter Cardiovasc Interv* 82:1031–8, 2013
- [119] Finn AV, Joner M, Nakazawa G et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialisation. *Circulation* 115:2435–41, 2007
- [120] Kim JW, Suh SY, Choi CU et al. Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus paclitaxel-eluting stent. *JACC Cardiovasc Interv* 1:65–71, 2008
- [121] Kim JW, Seo HS, Park JH et al. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction. *J Am Coll Cardiol* 53:1653–9, 2009
- [122] Okumura M, Ozaki Y, Ishii J et al. Restenosis and stent fracture following sirolimus-eluting stent (SES) implantation. *Circ J* 71(11):1669–77, 2007
- [123] Park JS, Cho IH, Kim YJ. Stent fracture and restenosis after zotarolimus-eluting stent implantation. *Int J Cardiol* 147:e29–31, 2011
- [124] Kim JS, Lee SY, Lee JM et al. Significant association of coronary stent fracture with in-stent restenosis in sirolimus-eluting stents. *Coron Artery Dis* 20:59–63, 2009
- [125] Watanabe T, Tamura A, Miyamoto K et al. Fracture of a paclitaxol-eluting stent implanted for in-stent restenosis at the site of sirolimus-eluting stent fracture. *Int J Cardiol* 140:e12–3, 2010
- [126] Bilen E, Saatci Yasar A, Bilge M et al. Acute coronary syndrome due to complete bare metal stent fracture in the right coronary artery. *Int J Cardiol* 139:e44–6, 2010
- [127] Toutouzas K, Patsa C, Tsiamis E et al. Everolimus- and zotarolimus-eluting stents for bare metal stent in-stent restenosis treatment: a prospective study. *J Interv Cardiol* 21:388–94, 2008
- [128] Meredith IT, Worthley SG, Whitbourn R et al. Long-term clinical outcomes with the next-generation Resolute Stent System: a report of the two-year follow-up from the RESOLUTE clinical trial. *Eurointervention* 5:692–7, 2010
- [129] Buiten RA, Ploumen EH, Zocca P et al. Thin composite-wire-strut zotarolimus-eluting stents versus ultrathin-strut sirolimus-eluting stents in BIONYX at 2 years. *JACC Cardiovasc Interv* 13:1100–9, 2020
- [130] Windecker S, Latib A, Kedhi E et al., on behalf of the ONYX ONE Investigators. Polymer-based or polymer-free stents in patients at high bleeding risk. *N Engl J Med* 382:1208–18, 2020
- [131] Ostojic M, Sagic D, Jung R et al. The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients

- with coronary artery disease: the NOBORI PK study. *Catheter Cardiovasc Interv* 72:901–8, 2008
- [132] Chevalier B, Serruys PW, Silber S et al. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. *Eurointervention* 2:426–34, 2007
- [133] Vetrovec GW, Rizik D, Williard C et al. Sirolimus PK trial: A pharmacokinetic study of the sirolimus-eluting Bx Velocity stent in patients with de novo coronary lesions. *Catheter Cardiovasc Interv* 67:32–7, 2006
- [134] Stella PR, Mueller R, Pavlakis G et al., Custom-II Investigators. One year results of a new in situ length-adjustable stent platform with a biodegradable biolimus A9 eluting polymer: results of the CUSTOM-II trial. *EuroIntervention* 4:200–7, 2008
- [135] Konishi A, Ho M, Shirai Y et al. First approval of improved medical device conditional on use-result survey in Japan – regulatory review of polymer-free drug-coated BioFreedom Coronary Stent. *Circ J* 82:1487–90, 2018
- [136] Lee SWL, Tam FCC, Chan KKW et al. Establishment of healing profile and neointimal transformation in the new polymer-free biolimus A9-coated coronary stent by longitudinal sequential optical coherence tomography assessments: the EGO-BIOFREEDOM study. *EuroIntervention* 14:780–8, 2018
- [137] Jensen LO, Maeng M, Raungaard B et al. Comparison of the polymer-free biolimus-coated BioFreedom stent with the thin-strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers population treated with percutaneous coronary intervention: rationale and design of the randomized SORT OUT IX trial. *Am Heart J* 213:1–7, 2019
- [137a] Jensen LO, Maeng M, Raungaard B et al., Sort Out IX Study Group. Randomized comparison of the polymer-free biolimus-coated BioFreedom stent with the ultrathin strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers population treated with percutaneous coronary intervention: the SORT OUT IX Trial. *Circulation* 141:2052–63, 2020
- [138] Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): a randomised non-inferiority trial. *Lancet* 372:1163–73, 2008
- [139] Stella PR, Mueller R, Pavlakis G et al., Custom-II Investigators. One year results of a new in situ length-adjustable stent platform with a biodegradable biolimus A9 eluting polymer: results of the CUSTOM-II trial. *EuroIntervention* 4:200–7, 2008
- [140] Verheye S, Agostoni P, Dubois CL et al. 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study. *J Am Coll Cardiol* 53:1031–9, 2009
- [141] Buysschaert I, Sanidas E, Hasegawa T et al. Baseline and 9 months IVUS analysis of the bifurcation-dedicated biolimus A9-eluting Axxess stent system: the DIVERGE IVUS substudy. *Catheter Cardiovasc Interv* 84:1062–70, 2014
- [142] Briguori C, Donahue M, Visconti G et al. Coronary artery bifurcation narrowing treated by Axxess stent implantation: the CARINAX registry. *Catheter Cardiovasc Interv* 89:e112–23, 2017
- [143] Borgia F, Niglio T, De Luca N et al. True double bifurcation lesions: new application of the self-expandable Axxess stent and review of literature with dedicated bifurcation devices. *Cardiovasc Revasc Med* 20:254–60, 2019
- [144] Buysschaert I, Verheye S. The Axxess stent. *EuroIntervention* 11(Suppl V): V143–4, 2015
- [145] Hamada N, Miyata M, Eto H et al. Tacrolimus-eluting stent inhibits neointimal hyperplasia via calcineurin/NFAT signaling in porcine coronary artery model. *Atherosclerosis* 208:97–103, 2010
- [146] Onuma Y, Serruys P, den Heijer P et al. MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de

- novo coronary stenoses. *Eur Heart J* 30:1477–85, 2009
- [147] Rinker A, Nusser T, Grossmann G et al. Angiographic results of a tacrolimus-eluting stent in acute coronary syndrome lesions. *Clin Res Cardiol* 98:89–93, 2009
- [148] Tamburino C, Di Salvo ME, Capodanno D et al. Real world safety and efficacy of the Janus tacrolimus-eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting STent (TEST) registry. *Catheter Cardiovasc Interv* 73:243–8, 2009
- [149] Aslanabadi N, Separham A, Beheshti R et al. OPTIMA tacrolimus-eluting stent: a twelve-month clinical follow up with two different periods of dual antiplatelet therapy; 2-month vs. 6-month approach. *J Cardiovasc Thorac Res* 4:81–4, 2012
- [150] Verheye S, Agostoni P, Dawkins KD et al. The GENESIS (randomized, multicenter study of the pimecrolimus-eluting and pimecrolimus/paclitaxel-eluting coronary stent system in patients with de novo lesions of the native coronary arteries) trial. *JACC Cardiovasc Interv* 2:205–14, 2009
- [151] Ormiston JA, Webster MW, Schwartz RS et al. Feasibility, safety, and efficacy of a novel polymeric pimecrolimus-eluting stent: traditional pre-clinical safety end points failed to predict 6-month clinical angiographic results. *JACC Cardiovasc Interv* 2:1017–24, 2009
- [152] Savvoulidis P, Perlman G, Bagur R. The EluNIRTM ridaforolimus eluting coronary stent system. *Expert Rev Med Devices* 16:71–6, 2019
- [153] Kandzari DE, Smits PC, Love MP et al. Randomized comparison of ridaforolimus- and zotarolimus-eluting coronary stents in patients with coronary artery disease: primary results from the BIONICS trial (BioNIR ridaforolimus-eluting coronary stent system in coronary stenosis). *Circulation* 136:1304–14, 2017
- [154] Paradies V, Ben-Yehuda O, Jonas M et al. A prospective randomised trial comparing the novel ridaforolimus-eluting BioNIR stent to the zotarolimus-eluting Resolute stent: six-month angiographic and one-year clinical results of the NIREUS trial. *EuroIntervention* 14:86–93, 2018
- [155] Konigstein M, Smits PC, Love MP et al. Randomized comparison of ridaforolimus-eluting and zotarolimus-eluting coronary stents 2-year clinical outcomes from the BIONICS and NIREUS Trials. *JACC Cardiovasc Interv* 13:86–93, 2020
- [156] Serruys PW, Ormiston JA, Sianos G et al., ACTION investigators. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. *J Am Coll Cardiol* 44:1363–7, 2004
- [157] Hildalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. *J Natl Cancer Inst* 93:178–93, 2001
- [158] Sierevogel MJ, Velema E, van der Meer FJ et al. Matrix metalloproteinase inhibition reduces adventitial thickening and collagen accumulation following balloon dilation. *Cardiovasc Res* 55:864–9, 2002
- [159] Pepine CJ, Hirshfeld JW, Macdonald RG et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group. *Circulation* 81:1753–61, 1990
- [160] Versaci F, Gaspardone A, Tomai F et al. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation study (IMPRESS Study). *J Am Coll Cardiol* 40:1935–42, 2002
- [161] New G, Moses JW, Roubin GS et al. Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model. *Catheter Cardiovasc Interv* 57:266–71, 2002
- [162] Chandrasekar B, Nattel S, Tanguay JF. Coronary artery endothelial protection after local delivery of 17 beta-estradiol during balloon angioplasty in a porcine model: a potential new pharmacologic approach to improve endothelial function. *J Am Coll Cardiol* 38:1570–6, 2001
- [163] Byrne RA, Kastrati A, Kufner S et al., Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Investigators. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. *Eur Heart J* 30:2441–9, 2009
- [164] Byrne R, Kastrati A, Massberg S et al. Bio-degradable polymer versus permanent po-

- lymer drug-eluting stents and everolimus-versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. *J Am Coll Cardiol* 58:1325–31, 2011
- [165] Stefanini G, Byrne RA, Serruys PW et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. *Eur Heart J* 33:1214–22, 2012
- [166] Kufner S, Joner M, Thannheimer A et al. Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease. *Circulation* 139:325–33, 2019
- [167] Xhepa E, Tada T, Cassese T et al. Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort. *Indian Heart J* 66:345–9, 2014
- [168] Aoki J, Serruys PW, van Beusekom H et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. *J Am Coll Cardiol* 45:1574–9, 2005
- [169] Nakazawa G, Granada JF, Alviar C. Anti-CD34 antibodies immobilized on the surface of sirolimus eluting stents enhances stent endothelialization. *JACC Cardiovasc Interv* 3:68–75, 2010
- [170] Woudstra P, Kalkman DN, den Heijer P et al. 1-year results of the REMEDEE Registry. Clinical outcomes after deployment of the abluminal sirolimus-coated bioengineered (Combo) stent in a multicenter, prospective all-comers registry. *JACC Cardiovasc Interv* 9:1127–34, 2016
- [171] Kalkman DN, Tijssen RYG, Kraak RP et al. 1-year clinical performance of COMBO stent versus Xience stent in all-comers patients with coronary artery disease. *JACC Cardiovasc Interv* 11:102–3, 2018 yyy
- [172] Chandrasekhar J, Kok MM, Kalkman DN et al. 1-year clinical outcomes of all-comers treated with 2 bioresorbable polymer-coated sirolimus-eluting stents: propensity score-matched comparison of the COMBO and ultrathin-strut Orsiro stents. *JACC Cardiovasc Interv* 13:820–30, 2020
- [172a] Christ G. Stents und Scaffolds. *J Kardiologie* 27:229–36, 2020
- [173] Nef HM, Abdel-Wahab M, Achenbach S et al. Medikamentenfreisetzende Koronarstents/Scaffolds und medikamentenbeschichtete Ballonkatheter. *Kardiologie* 12:12–26, 2017. Erratum in: *Kardiologie* 12:53–5, 2018
- [174] Vlaar PJ, Svilaas T, van der Horst IC et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. *Lancet* 371:1915–20, 2008
- [175] Awuor SO, Ettinger SE, Capecci LM et al. Graftmaster savior: Injury to a patent LIMA during pericardiectomy, when a covered stent came to the rescue. *Catheter Cardiovasc Interv* 93:e326–30, 2019
- [176] Stone GW, Abizaid A, Silber S et al. Prospective, randomized, multicenter evaluation of a polyethylene terephthalate micro-net mesh-covered stent (MGuard) in ST-segment elevation myocardial infarction: the MASTER Trial. *J Am Coll Cardiol* 60:1975–84, 2012
- [177] Dudek D, Brener SJ, Rakowski T et al. Efficacy of an embolic protection stent as a function of delay to reperfusion in ST-segment elevation myocardial infarction (from the MASTER Trial). *Am J Cardiol* 114:1485–9, 2014
- [178] Gracida M, Romaguera R, Jacobi F et al. The MGuard coronary stent: safety, efficacy, and clinical utility. *Vasc Health Risk Manag* 11:533–9, 2015
- [179] Wañha W, Mielczarek M, Gilis-Malinowska N et al. Safety and efficacy of embolic protection devices in saphenous vein graft interventions: a propensity score analysis-multicenter SVG PCI PROTECTA Study. *J Clin Med* 9:1198, 2020
- [180] Amoroso G, Vos NS, Van der Heyden JA et al. A prospective, postmarket study with the MGuard Prime Embolic Protection Stent in ST-segment elevation myocardial infarction: the International MGuard Prime Observational Study (IMOS Prime). *Catheter Cardiovasc Interv* 86(Suppl 1):S28–33, 2015
- [180a] <https://medscape.com.my/embolic-protection-stent/> (abgerufen 17.1.2023)

- [181] Secco GG, Serdoz R, Kilic ID et al. Indications and immediate and long-term results of a novel pericardium covered stent graft: Consecutive 5 year single center experience. *Catheter Cardiovasc Interv* 87:712–9, 2016
- [182] Lu H, Ijsselmuiden AJ, Grundeken MJ et al. First-in-man evaluation of the novel balloon delivery system STENTYS Xposition S for the self-apposing coronary artery stent: impact on longitudinal geographic miss during stenting. *EuroIntervention* 11:1341–5, 2016
- [183] van Geuns RJ, Tamburino C, Fajadet J et al. Self-expanding versus balloon-expandable stents in acute myocardial infarction: results from the APPOSITION II study: self-expanding stents in ST-segment elevation myocardial infarction. *JACC Cardiovasc Interv* 5:1209–19, 2012
- [184] Koch KT, Grundeken MJ, Vos NS et al. One-year clinical outcomes of the STENTYS Self-Apposing coronary stent in patients presenting with ST-segment elevation myocardial infarction: results from the APPOSITION III registry. *EuroIntervention* 11:264–71, 2015
- [185] van Geuns R-J, Yetgin T, La Manna A. STENTYS Self-Apposing sirolimus-eluting stent in ST-segment elevation myocardial infarction: results from the randomised APPOSITION IV trial. *EuroIntervention* 11:e1267–74, 2016
- [186] Naber CK, Pyxaras SA, Nef H et al. Final results of a self-apposing paclitaxel-eluting stent for the percutaneous treatment of de novo lesions in native bifurcated coronary arteries study. *EuroIntervention* 12:356–8, 2016
- [3] Haude M, Erbel R, Issa H et al. Subacute thrombotic complications after intracoronary implantation of Palmaz-Schatz stents. *Am Heart J* 126:15–22, 1993
- [4] Görges G, Haude M, Ge J et al. Intravascular ultrasound after low and high inflation pressure coronary artery stent implantation. *J Am Coll Cardiol* 26:725–30, 1995
- [5] Görges G, Ge J, Erbel R. Role of intravascular ultrasound in the evaluation of mechanisms of coronary interventions and restenosis. *Am J Cardiol* 81:91–5, 1998
- [6] Batchelor R, Dinh D, Brennan A et al., VCOR Investigators. Incidence, predictors and clinical outcomes of stent thrombosis following percutaneous coronary intervention in contemporary practice. *Heart Lung Circ* 29:1433–9, 2020
- [7] Rao K R, Reddy S, Kashyap JR et al. Acute coronary syndrome after 17 years of bare metal stent implantation: „very“ very late stent thrombosis. *Case Rep Cardiol* 2020:9628719, 2020
- [8] Cutlip DE, Windecker S, Mehran R et al., Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation* 115:2344–51, 2007
- [9] Watanabe Y, Sakakura K, Fujita H et al., REAL-ST Registry Investigators. Comparison of clinical characteristics of stent thrombosis between the right coronary artery and the left coronary artery – a sub-analysis of the REAL-ST Registry. *Circ J* 84:169–77, 2020
- [10] Taniwaki M, Räber L, Zaugg S et al. Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography. *Circulation* 133:650–60, 2016
- [11] Adriaenssens T, Joner M, Godschalk TC et al., Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort (PRESTIGE) Investigators. Optical coherence tomography findings in patients with coronary stent thrombosis: a report of the PRESTIGE consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort). *Circulation* 136:1007–21, 2016
- [12] Noaman S, O'Brien J, Andrianopoulos N et al., Melbourne Interventional Group Investigators. Clinical outcomes following ST-elevation myocardial infarction secondary to stent thrombosis treated by percu-

15.3.5–15.3.6 Stentthrombosen und -frakturen

- [1] Swars H, Hafner G, Erbel R et al. Prothrombin fragments and thrombotic occlusion of coronary stents. *Lancet* 337:59–60, 1991
- [2] Hafner G, Swars H, Erbel R et al. Monitoring prothrombin fragment 1+2 during initiation of oral anticoagulant therapy after intracoronary stenting. *Ann Hematol* 65:83–7, 1992

- taneous coronary intervention. *Catheter Cardiovasc Interv* 96:E406–14, 2020
- [13] Oba Y, Funayama H, Takahashi M et al. Stent fracture and thrombosis visualized by a combination of enhanced stent visualization and optical coherence tomography. *Coron Artery Dis* 31:660, 2020
- [14] Lopes RD, Leonardi S, Wojdyla DM et al. Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. *Circulation* 141:781–3, 2020
- [14a] Escaned J, Cao D, Baber U et al. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. *Eur Heart J* 42:4624–34, 2021
- [15] Açıkgoz SK, Açıkgoz E, Çiçek G. Value of CHA2DS2-VASc Score for prediction and ruling out of acute stent thrombosis after primary percutaneous coronary intervention. *Angiology* 71:411–6, 2020
- [15a] Wu H, Xu L, Zhao X et al., OPTION Investigators. Indobufen or Aspirin on top of Clopidogrel after coronary drug-eluting stent implantation (OPTION): a randomized, open-label, end point-blinded, noninferiority trial. *Circulation* 147:212–22, 2023
- [16] Virmani R, Kolodgie FD, Farb A. Drug-eluting stents: are they really safe? *Am Heart Hosp J* 2:85–8, 2004
- [17] Ladich E, Vorpahl M, Nakano M et al. Latest on the pathology of drug-eluting stents. *Interv Cardiol* 1:165–74, 2009
- [18] Cook S, Ladich E, Nakazawa G et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. *Circulation* 120:391–9, 2009
- [19] Ohno Y, Yamaji K, Kohsaka S et al. Incidence and in-hospital outcomes of patients presenting with stent thrombosis (from the Japanese Nationwide Percutaneous Coronary Intervention Registry). *Am J Cardiol* 125:720–6, 2020
- [20] Shite J, Matsumoto D, Yokoyama M. Sirolimus-eluting stent fracture with thrombus, visualization by optical coherence tomography. *Eur Heart J* 27:1389, 2006
- [21] Aoki J, Nakazawa G, Tanabe K et al. Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. *Catheter Cardiovasc Interv* 69:380–6, 2007
- [22] Lee MS, Jurewitz D, Aragon J et al. Stent fracture associated with drug-eluting stents: clinical characteristics and implications. *Catheter Cardiovasc Interv* 69:387–94, 2007
- [23] Lee SH, Park JS, Shin DG et al. Frequency of stent fracture as a cause of coronary restenosis after sirolimus-eluting stent implantation. *Am J Cardiol* 100:627–30, 2007
- [24] Shaikh F, Maddikunta R, Djelmami-Hani M et al. Stent fracture, an incidental finding or a significant marker of clinical in-stent restenosis? *Catheter Cardiovasc Interv* 71:614–8, 2008
- [25] Leong DP, Dundon BK, Puri R et al. Very late stent fracture associated with a sirolimus-eluting stent. *Heart Lung Circ* 17:426–8, 2008
- [26] Nakazawa G, Finn AV, Vorpahl M et al. Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis. *J Am Coll Cardiol* 54:1924–31, 2009
- [27] Park JS, Cho IH, Kim YJ. Stent fracture and restenosis after zotarolimus-eluting stent implantation. *Int J Cardiol* 147:e29–31, 2011
- [28] Park JS, Shin DG, Kim YJ et al. Acute myocardial infarction as a consequence of stent fracture and plaque rupture after sirolimus-eluting stent implantation. *Int J Cardiol* 134:e79–81, 2009
- [29] Popma JJ, Tiroch K, Almonacid A et al. A qualitative and quantitative angiographic analysis of stent fracture late following sirolimus-eluting stent implantation. *Am J Cardiol* 103:923–9, 2009
- [30] Biscaglia S, Tebaldi M, Tumscitz C et al. Prospective identification of stent fracture by enhanced stent visualization system during percutaneous coronary intervention. *Circ J* 81:82–9, 2017

15.4–15.10 PCI – Techniken, Nachbehandlung, Komplikationen, Fallbeispiel

- [1] Grüntzig A, Fischer M, Goebel N et al. Percutaneous transluminal coronary angioplasty (PTCA). Study of 147 patients. *Ann Radiol* 24:377–9, 1981
- [2] Meyer J, Schmitz H, Erbel R et al. Treatment of unstable angina pectoris with percutaneous transluminal coronary angioplasty (PTCA). *Cathet Cardiovasc Diagn* 7:361–71, 1981
- [3] Dorros G, Cowley MJ, Simpson J et al. Percutaneous transluminal coronary angioplasty: report of complications from the National Heart, Lung, and Blood Institute PTCA Registry. *Circulation* 67:723–30, 1983
- [4] Rupprecht HJ, Brennecke R, Kottmeyer M et al. Short- and long-term outcome after PTCA in patients with stable and unstable angina. *Eur Heart J* 11:964–73, 1990
- [5] Grüntzig A. Transluminal dilatation of coronary-artery stenosis. *Lancet* 1:263, 1978
- [6] Meier B, Bachmann D, Lüscher T. 25 years of coronary angioplasty: almost a fairy tale. *Lancet* 361:527, 2003
- [7] Schlumpf M. 30 Jahre Ballonkatheter: Andreas Grüntzig, ein Pionier in Zürich. *Schweiz Ärztezeitung* 85:347–51, 2004
- [8] Düber C, Jungbluth A, Rumpelt HJ et al. Morphology of the coronary arteries after combined thrombolysis and percutaneous transluminal coronary angioplasty for acute myocardial infarction. *Am J Cardiol* 58:698–703, 1986
- [9] Jungbluth A, Düber C, Rumpelt HJ et al. Morphology of the coronary arteries following percutaneous transluminal coronary angioplasty with hemopericardium. *Z Kardiol* 77:125–9, 1988
- [10] Waller BF. Morphologic observations in coronary arteries, aortocoronary saphenous vein bypass grafts and infant aortae following balloon angioplasty procedures. *Herz* 10:255–68, 1985
- [11] Waller BF, Orr CM, Pinkerton CA et al. Morphologic observations late after coronary balloon angioplasty: mechanisms of acute injury and relationship to restenosis. *Radiology* 174:961–7, 1990
- [12] Waller BF, Pinkerton CA, Orr CM et al. Morphological observations late (greater than 30 days) after clinically successful coronary balloon angioplasty. *Circulation* 83(Suppl 2):I28–41, 1991
- [13] Gerber TC, Erbel R, Gorge G et al. Classification of morphologic effects of percutaneous transluminal coronary angioplasty assessed by intravascular ultrasound. *Am J Cardiol* 70:1546–54, 1992
- [14] Schmitz HJ, Erbel R, Meyer J et al. Influence of vessel dilatation on restenosis after successful percutaneous transluminal coronary angioplasty. *Am Heart J* 131:884–91, 1996
- [15] Colombo A, Hall P, Nakamura S et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. *Circulation* 91:1676–88, 1995
- [16] Gorge G, Haude M, Ge J et al. Intravascular ultrasound after low and high inflation pressure coronary artery stent implantation. *J Am Coll Cardiol* 26:725–30, 1995
- [17] Frey AW, Hodgson JM, Müller C et al. Ultrasound-guided strategy for provisional stenting with focal balloon combination catheter: results from the randomized strategy for intracoronary ultrasound-guided PTCA and stenting (SIPS) trial. *Circulation* 102:2497–502, 2000
- [18] Cook S, Wenaweser P, Togni M et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. *Circulation* 115:2426–34, 2007
- [19] Fitzgerald PJ, Oshima A, Hayase M et al. Final results of the can routine ultrasound influence stent expansion (CRUISE) study. *Circulation* 102:523–30, 2000
- [20] Abizaid A, Kornowski R, Mintz G et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. *J Am Soc Cardiol* 2:584–9, 1998
- [21] Eyüboğlu M. In stent restenosis after percutaneous coronary intervention. *Anatol J Cardiol* 16:73, 2016
- [22] Rathore S, Terashima M, Katoh O et al. Predictors of angiographic restenosis after drug eluting stents in the coronary arteries: contemporary practice in real world patients. *EuroIntervention* 5:349–54, 2009
- [23] Kozuma K, Shinozaki T, Kozuma K et al. Impact of residual stenosis on the angiographic edge restenosis of a second-generation drug-eluting stent. *Int Heart J* 60:1050–60, 2019

- [24] Jiang H, Liu W, Liu Y et al. High levels of HB-EGF and interleukin-18 are associated with a high risk of in-stent restenosis. *Anatol J Cardiol* 15:907–12, 2015
- [25] Lee HY, Kim JH, Kim BO et al. Regular exercise training reduces coronary restenosis after percutaneous coronary intervention in patients with acute myocardial infarction. *Int J Cardiol* 167:2617–22, 2013
- [26] Choi JW, Goodreau LM, Davidson CJ. Resource utilization and clinical outcomes of coronary stenting: a comparison of intravascular ultrasound and angiographical guided stent implantation. *Am Heart J* 142:112–8, 2001
- [27] Russo RJ. Ultrasound-guided stent placement. *Cardiol Clin* 15:49–61, 1997
- [28] Gaster AL, Slothuus Skjoldborg U, Larsen J et al. Continued improvement of clinical outcome and cost effectiveness following intravascular ultrasound guided PCI: insights from a prospective, randomised study. *Heart* 89:1043–9, 2003
- [29] Schiele F, Meneveau N, Vuilleminot A et al. Impact of intravascular ultrasound guidance in stent deployment on 6-month restenosis rate: a multicenter, randomized study comparing two strategies – with and without intravascular ultrasound guidance. RESIST Study Group. REStenosis after Ivus guided STenting. *J Am Coll Cardiol* 32:320–8, 1998
- [30] Oemrawsingh PV, Mintz GS, Schali J et al. Intravascular ultrasound guidance improves angiographic and clinical outcome of stent implantation for long coronary artery stenoses: final results of a randomized comparison with angiographic guidance (TULIP Study). *Circulation* 107:62–7, 2003
- [31] Ge J, Erbel R, Gerber T et al. Intravascular ultrasound imaging of angiographically normal coronary arteries: a prospective study in vivo. *Br Heart J* 71:572–8, 1994
- [32] Moses JW, Weisz G, Mishkel G et al. The SIRIUS-DIRECT trial: a multi-center study of direct stenting using the sirolimus-eluting stent in patients with de novo native coronary artery lesions. *Catheter Cardiovasc Interv* 70:505–12, 2007
- [33] Ohlmann P, Mintz GS, Kim SW et al. Intravascular ultrasound findings in patients with restenosis of sirolimus- and paclitaxel-eluting stents. *Int J Cardiol* 125:11–5, 2008
- [34] Colombo A. Cutting balloon and the search for an optimal treatment for in-stent restenosis. *Ital Heart J* 5:280–1, 2004
- [35] de Ribamar Costa J Jr, Mintz GS, Carlier SG et al. Nonrandomized comparison of coronary stenting under intravascular ultrasound guidance of direct stenting without predilation versus conventional predilation with a semi-compliant balloon versus predilation with a new scoring balloon. *Am J Cardiol* 100:812–7, 2007
- [36] Biscaglia S, Tebaldi M, Tumscitz C et al. Prospective identification of stent fracture by enhanced stent visualization system during percutaneous coronary intervention. *Circ J* 81:82–9, 2016
- [37] Windecker S, Simon R, Lins M et al. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. *Circulation* 111:2617–22, 2005
- [38] Roy P, Torguson R, Okabe T et al. Angiographic and procedural correlates of stent thrombosis after intracoronary implantation of drug-eluting stents. *J Interv Cardiol* 20:307–13, 2007
- [39] Ali ZA, Maehara A, Genereux P et al. Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial. *Lancet* 388:2618–28, 2016
- [40] Kuku KO, Ekanem E, Azizi V et al. Optical coherence tomography-guided percutaneous coronary intervention compared with other imaging guidance: a meta-analysis. *Int J Cardiovasc Imaging* 34:503–13, 2018
- [41] Mudra H, Di Mario C, de Jaegere P et al., OPTICUS (OPTimization with ICUS to reduce stent restenosis) Study Investigators. Randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS Study). *Circulation* 104:1343–9, 2001
- [42] Koo BK, Kim YS, Park KW et al. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. *Lancet* 370:567–74, 2007

- [43] Sakurai R, Ako J, Morino Y et al., SIRIUS Trial Investigators. Predictors of edge stenosis following sirolimus-eluting stent deployment (a quantitative intravascular ultrasound analysis from the SIRIUS trial). *Am J Cardiol* 96:1251–3, 2005
- [44] Bagnall AJ, Spratt JC. The „buddy-in-jail“ technique – a novel method for increasing support during percutaneous coronary intervention. *Catheter Cardiovasc Interv* 4:6564–8, 2009

15.11 Bioabsorbierbare Stents

- [1] Byrne RA, Serruys PW, Baumbach A et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. *Eur Heart J* 36:2608–20, 2015
- [2] Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 35:2541–619, 2014
- [3] Wiebe J, Nef HM, Hamm CW. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. *J Am Coll Cardiol* 64:2541–51, 2014
- [4] Maeng M, Tilsted H, Jensen L et al. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre open-label, randomised superiority trial. *Lancet* 383:2047–56, 2014
- [5] Stone GW, Maehara A, Lansky AJ et al. A prospective natural-history study of coronary atherosclerosis. *N Engl J Med* 364:226–35, 2011
- [6] Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? *Eur Heart J* 33:16–25b, 2012
- [7] Otsuka F, Byrne RA, Yahagi K et al. Neo-atherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. *Eur Heart J* 36:2147–59, 2015
- [8] Serruys PW, Onuma Y, Dudek D et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. *J Am Coll Cardiol* 58 :1578–88, 2011
- [9] Serruys PW, Chevalier B, Sotomi Y et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. *Lancet* 388:2479–91, 2016
- [10] Ellis SG, Kereiakes DJ, Metzger DC et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. *N Engl J Med* 373:1905–15, 2015
- [11] Gao R, Yang Y, Han Y et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China Trial. *J Am Coll Cardiol* 66:2298–309, 2015
- [12] Kimura T, Kozuma K, Tanabe K et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. *Eur Heart J* 36:3332–42, 2015
- [13] Sabaté M, Windecker S, Iñiguez A et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. *Eur Heart J* 37:229–40, 2016
- [14] Wykrzykowska J, Kraak R, Hofman S et al. Bioresorbable scaffolds versus metallic stents in routine PCI. *N Engl J Med* 376:2319–28, 2017
- [15] Stone GW, Gao R, Kimura T et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. *Lancet* 387:1277–89, 2016
- [16] Sorrentino S, Giustino G, Mehran R et al. Everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents. *J Am Coll Cardiol* 69:3055–66, 2017

- [17] Ishibashi Y, Nakatani S, Sotomi Y et al. Relation between bioresorbable scaffold sizing using QCA-Dmax and clinical outcomes at 1 year in 1,232 patients from 3 study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). *JACC Cardiovasc Interv* 8:1715–26, 2015
- [18] Ormiston JA, Serruys PW, Onuma Y et al. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. *Circ Cardiovasc Interv* 5:620–63, 2012
- [19] Ellis SG, Kereiakes DJ, Metzger DC et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. *N Engl J Med* 373:1905–15, 2015
- [20] Suwannasom P, Sotomi Y, Ishibashi Y et al. The impact of post-procedural asymmetry, expansion, and eccentricity of bioresorbable everolimus-eluting scaffold and metallic everolimus-eluting stent on clinical outcomes in the ABSORB II Trial. *JACC Cardiovasc Interv* 9:1231–42, 2016
- [21] Puricel S, Cuculi F, Weissner M et al. Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. *J Am Coll Cardiol* 67:921–31, 2016
- [22] Abizaid A, Costa RA, Schofer J et al. Serial multimodality imaging and 2-year clinical outcomes of the novel DESolve novolimus-eluting bioresorbable coronary scaffold system for the treatment of single de novo coronary lesions. *JACC Cardiovasc Interv* 9:565–74, 2016
- [23] Wiebe J, Dörr O, Ilstad H et al. Everolimus- versus novolimus-eluting bioresorbable scaffolds for the treatment of coronary artery disease: a matched comparison. *JACC Cardiovasc Interv* 10:477–85, 2017
- [24] Haude M, Ince H, Abizaid A et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. *Lancet* 387:31–9, 2016
- [25] Haude M, Ince H, Abizaid A et al. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. *Eur Heart J* 37:2701–9, 2016
- [26] Haude M, Tölg R et al. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: 3-year clinical results and angiographic findings of the Biosolve-II first-in-man trial. *EuroIntervention* 23:432–9, 2017
- [27] Haude M, Erbel R, Erne P et al. Safety and performance of the Drug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. *EuroIntervention* 12:e160–6, 2016
- [28] Haude M, Ince H, Kische S et al. Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of Biosolve-II and Biosolve-III. *EuroIntervention* 13:432–9, 2017
- [29] Waksman R, Zumstein P, Pritsch M et al. Second-generation magnesium scaffold Magmaris: device design and preclinical evaluation in a porcine coronary artery model. *EuroIntervention* 13:440–9, 2017
- [30] Abizaid A, Carrié D, Frey N et al. 6-month clinical and angiographic outcomes of a novel radiopaque sirolimus-eluting bioresorbable vascular scaffold: The FANTOM II Study. *JACC Cardiovasc Interv* 10:1832–8, 2017
- [31] La Manna A, Chisari A, Giacchi G et al. Everolimus-eluting bioresorbable vascular scaffolds versus second generation drug-eluting stents for percutaneous treatment of chronic total coronary occlusions: technical and procedural outcomes from the GHOST-CTO registry. *Catheter Cardiovasc Interv* 88:e155–63, 2016
- [32] Kawamoto H, Ruparel N, Tanaka A et al. Bioresorbable scaffolds for the management of coronary bifurcation lesions. *JACC Cardiovasc Interv* 989–1000, 2016
- [33] Capodanno D, Gori T, Nef H et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. *EuroIntervention* 10:1144–53, 2015

- [34] Rottländer D, Schneider T, Degen H et al. Lesion preparation with cutting balloon angioplasty is associated with coronary aneurysm formation in polylactide biodegradable vascular scaffold implantation. *EuroIntervention* 13:e1483–6, 2017
- [35] Verheye S, Wlodarczak A, Montorsi P et al. BIOSOLVE-IV-registry: safety and performance of the Magmaris scaffold: 12-month outcomes of the first cohort of 1,075 patients. *Catheter Cardiovasc Interv* 98(1):E1–E8, 2021